Please enter the email address you used to register, then we will send you a link to choose a new password
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target ...
-SEC Filing
U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower.
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...
Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announ...
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...
https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm